GLP1R and type 2 diabetes mellitus: In addition to the actions of GLP-1 discussed above, the long acting analogs have also in long-term cardiovascular outcome studies been demonstrated to result in reduced cardiovascular risk, so far only in patients with both T2DM and cardiovascular risk (95, 118, 119), but emerging evidence suggests that this may also apply to individuals without established heart disease.